Paxil CR returns
Executive Summary
GlaxoSmithKline resumes shipment of Paxil CR, four months after manufacturing problems led to FDA's seizure of the product at distribution and production facilities (1"The Pink Sheet" March 21, 2005, p. 15). Sales reps will offer 30-day free trial vouchers to support reintroduction; Paxil CR will be a "priority" for sales force, GSK says. Resupply of Avandamet, which also was seized by FDA, is projected to begin by mid-July...
You may also be interested in...
FDA Expects Consent Decree For GSK As Follow-Up To Seizure Action
FDA expects to enter into a consent decree with GlaxoSmithKline to resolve manufacturing violations at its Cidra, Puerto Rico facility following the seizure of Paxil CR and Avandamet
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.